Beijing Wannianchun Biological Medicine High Technology

Beijing Wannianchun Biological Medicine High Technology is a Chinese biopharmaceutical company founded in 2000 and headquartered in Beijing. The company is dedicated to the research and development of innovative small molecule drugs, particularly in the field of urogenital health. Its lead product, Aildenafil Citrate (brand name Ailisi), is a potent and selective PDE5 inhibitor that was approved by the NMPA in December 2021 for the treatment of male erectile dysfunction. Beijing Wannianchun collaborates with Yuekang Pharmaceutical Group for the commercialization and marketing of Aildenafil Citrate in China. The company continues to conduct post-marketing clinical trials to further establish the safety and efficacy profile of its flagship drug.